• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 4. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 5. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Recent Advances in the Study of N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride (CAS: 1219964-16-5)

N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride (CAS: 1219964-16-5) is a compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential applications in drug development, particularly in the modulation of neurotransmitter systems. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and therapeutic potential.

One of the key areas of investigation has been the compound's role as a potential modulator of the cholinergic system. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride exhibits high affinity for nicotinic acetylcholine receptors (nAChRs). The research team employed molecular docking simulations and in vitro binding assays to elucidate the compound's interaction with α7 nAChR subtypes, suggesting its potential utility in treating cognitive disorders such as Alzheimer's disease.

In addition to its neurological applications, recent research has explored the compound's pharmacokinetic profile. A 2024 study in Drug Metabolism and Disposition reported that N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride demonstrates favorable bioavailability and blood-brain barrier penetration in rodent models. The study utilized LC-MS/MS techniques to quantify the compound's distribution in various tissues, providing valuable data for future drug development efforts.

The synthetic chemistry of this compound has also seen advancements. A novel, more efficient synthetic route was reported in Organic Process Research & Development (2023), achieving a 78% overall yield with improved purity profiles. This development is particularly significant for scaling up production for preclinical studies. The new synthetic approach employs a reductive amination strategy that reduces the number of purification steps while maintaining high enantiomeric purity.

Recent toxicological studies have provided important safety data. Research published in Regulatory Toxicology and Pharmacology (2024) conducted comprehensive acute and subchronic toxicity evaluations in multiple animal models. The results indicated that N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride has a favorable safety profile at therapeutic doses, with no significant organ toxicity observed in 28-day repeated dose studies.

Looking forward, several research groups have initiated investigations into structural analogs of N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride to optimize its pharmacological properties. Preliminary results from these structure-activity relationship (SAR) studies suggest that modifications to the pyrrolidine moiety may enhance receptor subtype selectivity while maintaining the desired pharmacokinetic characteristics.

In conclusion, the growing body of research on N-Methyl-N-(3-pyrrolidinylmethyl)-1-butanaminedihydrochloride (CAS: 1219964-16-5) demonstrates its potential as a promising scaffold for CNS-targeted therapeutics. The compound's unique pharmacological profile, combined with recent advances in its synthesis and formulation, positions it as an important candidate for further drug development efforts in neurological and psychiatric disorders.

• 13005-11-3((1-Methylpyrrolidin-3-yl)methanamine)
• 51388-01-3((1-Ethylpyrrolidin-3-yl)methylamine)
• 86732-28-7(2-methyloctahydropyrrolo[3,4-c]pyrrole)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)